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Context. The popularity of 
Homeopathy
? The World Health Organisation estimate that 500 million people worldwide use 
homeopathy (WHO 2005)
? In the UK it is estimated that 15% of the population use and trust Homeopathy (TGI 
2008).
? Homeopathy  has also always been a part of the  state funded National Health 
Service in the UK (since it began in 1948)
? There are currently  four homeopathic NHS hospitals receiving 55,000 referrals a 
year
? 400 General Practitioners practise homeopathy, treating 200,000 patients per year 
with homeopathic medicine within primary care.(British homeopathic Association 
2009).
The importance of HPTs to 
Homeopathy
? HPTs ( often referred to as provings) remain one of the 
major sources of knowledge and data for the practice of 
homeopathic medicine
? Homeopathy is based on the idea of similars, that 'like 
cures like'.
? For 200 years, researchers have tested homeopathic 
medicines on healthy persons, observing symptoms 
which follow and using those observations as the basis for 
using the same medicines in those who are ill.
Are HPTs reliable?
? From the perspective of much of modern science and of health research, 
homeopathy  appears implausible.
? From a critical perspective the symptoms observed in HPT's might be due 
to various sorts of bias rather than being genuine pathogenetic effects, 
'caused' by the medicine.
? Many published HPTs appear to attribute all symptoms that are reported by 
participants during a trial to pathogenetic effects of the medicine.
Possible sources of bias in HPTs
• The absence of a control group ( due to temporal effects and/or regression to the 
mean)
• The absence of random allocation
• The absence of blinding
• The inclusion of trivial and pre existing symptoms
• The lack of a definition of a healthy volunteer
• The use of well known friends as volunteers
• The sudden prohibition of all medicinal drugs and foodstuffs.
Existing reviews of HPTs
Dantas et al reviewed the quality of HPT's  in a paper published in Homeopathy 
entitled  “A systematic review of the quality of homeopathic  pathogenetic trials 
published from 1945 to 1995”. The paper was not published until 2007 
( Homeopathy 2007 96)
They highlighted the poor methodological  quality of most HPTs and the results of this. 
For example two trials of the same medicine showed a 5000% difference in the 
number of symptoms reported, the difference seemingly related to a significant 
difference in quality.
I  aimed to update and expand on this work by looking at quantitative as well as 
qualitative data
Title and aim of the review
To determine whether the effects of homeopathic 
substances (ultra molecular dilutions) on human 
subjects differ from the effects of placebo in 
homeopathic pathogenetic trials. (HPTs)
Inclusion criteria for this 
systematic review
• This review only included studies with the following features 
• Participants  -Adults aged 18+
• Interventions - The ingestion of one or more doses of homeopathic substances 
(ultra molecular dilutions).
• Comparators - Studies which reported comparing homeopathic medicines to 
identical placebo medicines. 
• Outcomes -any outcome relating to symptoms experienced at any point in the
duration of the trials. Methods for recording symptoms include the daily 
completion of an unstructured diary by participants, structured diaries and 
specially developed proving questionnaires.
• Study Designs - RCTs
Searching the literature 1 -
Databases
Database Date Range
OVID MEDLINE Jan 1996-May 2009 ( 
wk 4)
AMED Jan 1996-May 2009 ( 
wk 4)
EMBASE Jan 1996-May 2009 ( 
wk 4)
CINAHL Jan 1996-May 2009 ( 
wk 4)
HOMINFORM All dates
LILACS ( English 
language only)
Jan 1996-May 2009 ( 
wk 4)
Included studies
• Title and abstracts identified and screened                     - n = 503
• Excluded                                                        - n = 487
• Full copies retrieved and assessed for eligibility              - n = 17
• Additional studies identified after contact with experts        - n = 1
• Excluded – not relevant design                                           - n =6
• Excluded – no outcomes                                                    - n =1
• Publications meeting inclusion criteria                         - n = 11
• Number of studies included in the review                        - n =15
Included studies
• Brien S, Lewith G and Bryant T (2003) S. Brien, G. Lewith, T. Bryant, Ultramolecular homeopathy has no observable clinical 
effects. A randomized, double-blind, placebo-controlled proving trial of Belladonna 30C British Journal of Clinical Pharmacology
2003;56(5): 562-568
• Dominici G et al (2006) Double blind,placebo controlled homeopathic pathogenetic trials: symptom collections and analysis Homeopathy 95,123-
130
• Goodyear K Lewith G and Low JL (1998) Randomised  Double blind,placebo controlled trial of homeopathic proving for Belladonna C30 Jrnl of the 
Royal Society of Medicine 91 579-582
• Fisher P and Dantas F (2001) Homeopathic pathogenetic trials of Acidum Malicum and Acidum Ascorbicum  British Homeopathic Journal 90 118-
125
• Mollinger H Schneider R and Walach H (2009) Homeopathic pathogenetic trials produce specific symptoms different from placebo Forsch 
Komplementmed 16 105-110
• Signorini A et al  Classical and new proving methodology: provings of Plumbum metallicum and Piper methysticum and comparison with a 
classical proving of Plumbum metallicum.Homeopathy. 2005 Jul;94(3):164-74.  
• Vickers A McCarneyR  Fisher P and Van Haselen R (2001) Can homeopaths detect homeopathic medicines? A pilot study for a randomised 
double blind placebo controlled investigation of the proving hypothesis. British Homeopathic Journal 90 126-130
• Walach H et al ( 2001) the effects of Homeopathic Belladonna 30CH in healthy volunteers – a randomised, double blind experiment. Jrnl of 
Psychosomatic Research 50 155-160
• Walach H et al (2004) Homeopathic proving symptoms result of a local non local or placebo process? A blinded placebo controlled pilot study 
Homeopathy 93 179-185
• Walach H et al (2008) Homeopathic pathogenetic trials produce more specific symptoms than non specific symptoms: results from two double 
blind placebo controlled trials. Jrnl of psychopharmacology 22(5) 543-55
Issues and dilemmas
• Idiosyncratic symptoms or those known in 
Homeopathy  as ' strange rare and peculiar' 
are thought to be very significant in HPTs, 
and to provide strong clues for prescribing.
• They occur in few or no volunteers in small 
HPTs and may be discounted in studies 
which focus on exclusively quantitative 
statistical analysis.
Issues and dilemmas
• On the one hand symptoms which occur during an HPT in only one or a 
small number of participants may be chance occurences, attributable to 
what might be termed ‘background noise’.
• On the other hand such rare symptoms may be genuine pathogenetic
effects. Homeopaths believe that such symptoms are often subsequently 
shown to be very reliable prescribing indicators in practice.
• Kaptchuk (1996) has concluded that “homeopathy still has no clear answer 
to the question of rare symptoms versus chance symptoms in provings”. 
Issues and dilemmas
• Homeopathic theory suggests that only people who are 
sensitive or susceptible to a particular homeopathic 
medicine will respond to it – the idea of individualising. 
• This is true in clinical practice and also in HPTs
• Evidence from the trials included in this review 
suggests that proving reactions and pathogenetic 
effects are unlikely to occur in more than 14% of a 
random sample of the population. ( see also Goodyear 1998)
Issues and dilemmas
• Levels of nocebo symptoms in any random sample of the 
population are likely to be at least at the same level. 
( Kaptchuk 1996, Green 1964)
• Therefore HPTs which involve random samples of the 
population are unlikely to show quantitative differences 
between placebo and intervention groups.
Key findings
• Only 3% of studies located met the inclusion 
criteria
• None of the studies that met the criteria used 
any screening procedures for selecting 
participants for sensitivity to the medicine 
being tested.
Findings – proving reactions
• A number of researchers adopted the strategy of pre-defining a proving 
reaction and then assessing how many participants demonstrated this. 
• Defined as e.g 2 true symptoms on 2 consecutive days and no false 
symptoms.
• Results according to proving reactions were as follows
Study                         Participants showing a proving reaction
• Vickers and Van H          4/52 ( 8%)    verum 
1/52 (2%)    placebo
• Goodyear                         5/20 (25%)  verum
1/27 ( 3.%)    placebo
• Brien                                14 /101(13.9%) verum
15/105 (14.3%) placebo
Meta analysis
• Pooling of the heterogeneous outcomes from 
the three trials showed no significant 
differences 
Figure 3.11  Meta analysis ( fixed effects model)  Participants showing a proving 
reaction.
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Symptoms typical of the test 
medicine
• The other approach to measuring outcomes which was typically taken 
was to pre-define symptoms which would be typical of the test medicine 
( based on previous trials or other sources of knowledge)
• Nine of the included studies used such measures. Three of these 
reported significant differences between verum and placebo groups. 
Only one of these three had statistical data which was suitable for 
pooling.
• Thus no statistical significance was found on these measures.
Limitations of the study
• Publication bias
• Trial size – 9 of the 15 studies included has less than 50 
participants
• Language bias – the study was limited to trials which were 
fully available in English
• Lack of screening participants for sensitivity to the 
homeopathic medicine
Recommendations.
• It is recommended that , in order to reduce bias, and to increase  the 
likelihood of distinguishing genuine pathogenetic effects from placebo 
effects and background noise, study designs for HPTs should include:
• Randomisation, using explicit procedures
• Use of placebo comparator groups
• Blinding of participants and researchers and verification of blinding
• Dealing with loss to follow up and adverse events appropriately.
• Using validated outcomes measures
• Operationalising the definition of health which is used as a standard 
inclusion criteria for HPTs. The use of the SF36, or some other well 
validated and widely used measure is suggested.
Recommendations
• It is important that techniques are developed for screening participants 
for sensitivity/susceptibility to the medicine used in the trial (Vithoulkas
2000, Herscu 2002)
• The REDHOT guidelines (Reporting Data on homeopathic Treatments 
(RedHot ): A supplement to CONSORT, Dean et al 2006 )which were 
specifically developed  to improve the conduct and reporting of trials in 
homeopathy should be updated to include guidance specifically relating 
to the design, conduct and reporting of HPTs.
